EPL Ventures Buys Half The Outstanding Shares Of Bioinformatics Co. | GenomeWeb

MIAMI--EPL Ventures here has entered into a $5 million option agreement to buy half of the outstanding shares of bioinformatics software company Savant Bio medical. Savant acquires and manages bioinformatics software, DNA sequencing database products and services, and cell and gene research technology and products.

The deal involves a private placement of 2.4 million units at a price of 25 cents each. A unit consists of one common share and a share purchase warrant entitling the holder to buy another share for $1 within one year of the date of acquisition of the units.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.